Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, alone, or in combination with pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. These results follow end-of-treatment data presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2024, which demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (<1000 IU/mL) in both combination regimens.
Vir Biotechnology will present the following abstracts:
SOLSTICE Week 24 subgroup analysis: Impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran
Session: Poster Tour - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Date: Thursday, May 8
Time: 16:15 – 17:00h CET
Presenter: Alina Jucov, M.D., Ph.D., Arensia Exploratory Medicine GmbH, Düsseldorf, Germany, and Nicolae Testemitanu, State University of Medicine and Pharmacy, Chişinău, Moldova
This poster will also be available as part of the following session:
Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies, or strategies
Date: Thursday, May 8
Time: 08:30 – 17:00h CET
Outcomes of 48 weeks of therapy and subsequent 24-week post-treatment period with tobevibart (VIR-3434) and elebsiran (VIR-2218) with or without Pegylated Interferon Alfa-2a in chronic hepatitis B virus infection. Findings from the MARCH Study
Session: General session 2
Date: Friday, May 9
Time: 10:30 – 12:30h CET
Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus
Session: Poster - Viral Hepatitis: Experimental and pathophysiology
Date: Friday, May 9
Time: 08:30 – 17:00h CET
Presenter: Dr. Gregory Camus, Director, Research, Vir Biotechnology, Inc.
About Tobevibart and Elebsiran
Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen (HBsAg). It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor's Xtend™ technology to extend half-life. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta and patients with chronic hepatitis B.
Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) discovered by Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta and patients with chronic hepatitis B.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'should,' 'could,' 'may,' 'might,' 'will,' 'plan,' 'potential,' 'aim,' 'expect,' 'anticipate,' 'promising' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the therapeutic potential of the combination of tobevibart and elebsiran to treat chronic hepatitis B (with or without PEG-IFNα) and chronic hepatitis delta; Vir Biotechnology's plans for presenting data from the SOLSTICE and MARCH studies at the EASL Congress 2025; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology's planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology's competitors, as well as changes in expected or existing competition; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology's available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology's filings with the U.S. Securities and Exchange Commission, including the section titled 'Risk Factors' contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
‘We were definitely very relieved;' Mahomet mother wins court case to keep autistic son's trampoline and their home
MAHOMET, Ill (WCIA) — A mother in Mahomet is breathing a sigh of relief after she won a court case keeping her from being evicted from her home. Angela Palivos said that after more than two years of back and forth with threats of eviction, she is finally able to feel secure at her home in Candlewood Estates. According to her, it was over a trampoline and swing set in her yard. She said they've been there to help her son, Elijah Sisney, with his autism for years. 'He loves to swing with children that are autistic,' Palivos said. 'They like the repetition.' 'We knew he was fighting': Chatham community mourns fifth death in kids camp tragedy But new management took over the trailer park three years ago, and Palivos said they had a problem with both pieces of equipment. 'In April, May of 2023, they issued those new leases and the rules and regulations,' Palivos said. The new leases banned trampolines from people's yards, but Palivos said hers is necessary for her son's wellbeing. 'The trampoline, that's his favorite,' she said. 'He likes to lay on his back and just bounce and listen to his music. It's his happy place. It's safe for him.' Palivos said she had a doctor's note backing up her claims and sent it to management. But it was only met with violations from the leasing agency. In September of last year, the company filed for eviction. 'I told them, 'Look, I need these things in place,'' Palivos said. 'I'm willing to sign a waiver, to not hold this company responsible for any accidents that may happen.' Palivos said she even agreed to move both off her property if Candlewood Estates would move the abandoned trailer next to hers. She said they refused. UPDATE: Rantoul Police ID suspect in 8-year-old's stabbing The two parties went to court, and last week, the judge ruled in favor of Palivos. 'They broke Illinois's Human Rights Act, and they also broke the Americans with Disabilities Act by not requesting a reasonable accommodation,' Palivos said. 'We were definitely very relieved.' Worries like this have even made it to State Senator Chapin Rose. He said complaints have been sent to Springfield for more than a year. 'They have treated the residents horrifically,' Rose said. 'It's about damn time, frankly, that the State of Illinois stepped up as they have.' Palivos' lawyer said Candlewood Estates has 30 days to file an appeal. Management declined an interview with WCIA. Palivos said she's happy to get back into her normal routine and is excited her son can have his happy place for years to come. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
37 minutes ago
- Yahoo
Dickcissel makes rare appearance at Alligator River National Wildlife Refuge
MANTEO, N.C. (WNCT) — A Dickcissel bird visit the Alligator River National Wildlife Refuge, which is unusual for this time of year. According to a press statement, 'Alligator River National Wildlife Refuge sometimes has rare visitors, including this male Dickcissel who was singing loudly beside the road on Milltail Road. Dickcissels are field birds that summer in the plains states and winters in Central and South America.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
37 minutes ago
- Yahoo
Texas Cyber Command signed into law: What this means for Texans
AUSTIN (KXAN) — On Monday, Texas Gov. Greg Abbott signed House Bill 150, which creates a state-based cybersecurity department, into law. The Texas Cyber Command was passed during the 89th regular legislative session and is expected to help protect Texans against cyber threats. RELATED | Lawmakers file bills to create Texas Cyber Command 'Our state is under constant attack by cyber criminals, attacks that occur thousands of times every single second of every single day,' Abbott said. 'I'm signing a law that creates the Texas Cyber Command. Its ultimate mission is to prevent and protect against cyber breaches. Working together with the Texas Cyber Command, Texas will be on the path to be a national leader in cybersecurity.' According to the governor's office, the Texas Cyber Command will: Launch a cyber threat intelligence center to identify and repair weaknesses and to educate users on preventing cyber breaches Coordinate with governments on responses to cyberattacks Collaborate with local, state and federal partners to establish 'the gold standard for cybersecurity' RELATED | Is your data safe? Lawmakers say it's time for a Texas Cyber Command The department, which is headquartered in San Antonio, was funded through a $135 million investment, according to the governor's office. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
